# OnCo record ewing-sarcoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/ewing-sarcoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "ewing-sarcoma" ;
  schema:name "Ewing sarcoma"@en ;
  schema:description "Ewing sarcoma is a bone and soft-tissue cancer of teenagers driven by a single fusion gene, EWSR1-FLI1. Intensive chemotherapy with surgery or radiation cures most localised cases; disease that has spread at diagnosis, and relapse, remain hard to treat, and no drug against the fusion protein itself has yet succeeded."@en ;
  schema:url <https://onco.cc/cancers/ewing-sarcoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ewing_sarcoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1138580> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418>, <https://www.cancer.gov/types/bone/patient/ewing-treatment-pdq> ;
  onco:tag "gap-fill", "paediatric", "sarcoma", "aya" ;
  onco:related <https://onco.cc/cancers/osteosarcoma/>, <https://onco.cc/cancers/rhabdomyosarcoma/>, <https://onco.cc/cancers/chondrosarcoma/>, <https://onco.cc/cancers/synovial-sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/limb-salvage-surgery/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/ewsr1-fli1/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/tk216/> ;
  onco:companies <https://onco.cc/companies/pharmamar/>, <https://onco.cc/companies/jazz/>, <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:pathways <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/histological-response-induction/> ;
  onco:trials <https://onco.cc/trials/ccss/>, <https://onco.cc/trials/cabone/>, <https://onco.cc/trials/regobone/>, <https://onco.cc/trials/sarc028/> ;
  onco:journals <https://onco.cc/journals/journal-of-adolescent-and-young-adult-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/lurbinectedin/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/drugs/kc1036/> ;
  onco:standardOfCare <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/limb-salvage-surgery/>, <https://onco.cc/trials/aews0031/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/cyclophosphamide/> .